Access to Medicine Index 2022

Webinar: SRHR Special Report

Anne-Charlotte Douard, Government engagement and policy officer
Amsterdam, Netherlands
About the Foundation

• The Access to Medicine Foundation mobilises healthcare companies to solve chronic issues of availability and affordability, so that more people in low- and middle-income countries (LMICs) can access vital healthcare products.
• Founded in 2005, the Foundation has published its Access to Medicine Index since 2008, and the AMR Benchmark since 2018.
• The Foundation is an independent non-profit organisation and it does not receive any funding from the pharmaceutical industry.
Access to medicine: media coverage

**Reuters**

Big pharma not doing enough to improve drug access - analysis

**Fierce Pharma**

GSK, J&J and AZ top global drug access index, but foundation says plenty more work needs to be done

**The Hindu**

Access plans increasingly part of drugmakers' strategies, says report

**SciDevNet**

Drugs companies must address ‘chronic neglect’ of women

**Swissinfo.ch**

Swiss pharma giants fall in access to medicine ranking

**PHARMA FAKTEN**

Eins Initiative von Arzneimittelherstellern in Deutschland

**Taarif**

Era of COVID-19 Has Seen More Companies Move To Address Access To Medicine. Will They Now Go Further?

**Access to medicineFOUNDATION**

GSK, J&J, and AZ head this year’s access to medicines ranking

**nrc**

Farmaceutische bedrijven spannen zich meer in voor arme landen, maar allerarmste vaak over hoofd gezien
Working with global health stakeholders to advance access
130+ investors managing assets over USD 21 trillion
Encouraging all 20 companies to take action
MISSION
Stimulate and guide essential healthcare companies to bring their products to people in low- and middle-income countries

OUTPUT
- Identify critical issues
- Build consensus on the role of industry in access
- Perform in-depth analysis of data and provide original insights
- Research reports illustrating opportunities for each company to do more, accompanying best practices

CONVENING POWER

DRIVE ACTION

GLOBAL HEALTH ORGANISATIONS

GOVERNMENTS

INVESTORS

THE PUBLIC

INDUSTRY

Improve buy-in and endorsement of access at CEO/Board level
Empower internal access teams

CONVENING POWER

OUTCOME
Companies make progress on their access to medicine policies and practices

IMPACT
More people in low-and middle income countries have access to healthcare products
Access to Medicine Index 2022
What we measure
**Scope**

**COMPANY SCOPE**
20 companies
Selected based on a combination of market capitalisation and relevance of pipeline and portfolio for access to medicine

**GEOGRAPHIC SCOPE**
108 low- and middle-income countries

**DISEASE SCOPE**
83 diseases, conditions and pathogens
- 23 Communicable Diseases
- 18 Non-Communicable Diseases
- 20 Neglected Tropical Diseases
- 10 Maternal & Neonatal Health Conditions
- 12 Priority Pathogens

**PRODUCT TYPE SCOPE**
- Medicines, microbicides, preventive vaccines, therapeutic vaccines
- Vector control products, platform technologies, diagnostics
- Contraceptive methods and devices
Analytical framework for the 2022 Index

<table>
<thead>
<tr>
<th>3 TECHNICAL AREAS</th>
<th>14 PRIORITY TOPICS</th>
<th>Indicators per topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>A  GOVERNANCE OF ACCESS 15%</td>
<td>Responsible business practices 4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Governance and strategy 3</td>
<td></td>
</tr>
<tr>
<td>B  RESEARCH &amp; DEVELOPMENT 30%</td>
<td>Access planning 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Product development 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Building R&amp;D capacity 1</td>
<td></td>
</tr>
<tr>
<td>C  PRODUCT DELIVERY 55%</td>
<td>Equitable access strategies 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Intellectual property strategy 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Quality and supply 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Licensing quality 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Product donations 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Registration 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inclusive business models 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Local manufacturing 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Health systems strengthening 1</td>
<td></td>
</tr>
</tbody>
</table>
Access to Medicine Index 2022
Publication overview
Scale & scope

KEY FINDINGS

TECHNICAL AREAS

DETAILED COMPANY REPORT CARDS

BEST PRACTICES

SPECIAL REPORTS
Access to Medicine Index 2022

Special Report: Sexual & Reproductive Health & Rights
R&D pipeline is focused on cancer

- **Breast cancer**: 28 Discovery/pre-clinical, 20 Phase I, 11 Phase II, 3 Phase III
- **Ovarian cancer**: 21 Discovery/pre-clinical, 7 Phase I, 8 Phase II
- **HIV/AIDS**: 5 Discovery/pre-clinical, 4 Phase I, 5 Phase II
- **Hepatitis B**: 9 Discovery/pre-clinical, 5 Phase I, 5 Phase II
- **Cervical cancer (including HPV-related)**: 8 Discovery/pre-clinical, 6 Phase I, 2 Phase II, 2 Discovery/pre-clinical
- **Uterine cancer**: 5 Discovery/pre-clinical, 4 Phase I, 3 Phase II
- **Endometriosis**: 2 Discovery/pre-clinical
- **Gonorrhoea**: 2 Discovery/pre-clinical
- **Chlamydia**: 2 Discovery/pre-clinical
- **M. genitalium**: 2 Discovery/pre-clinical
- **Maternal haemorrhage (incl. postpartum haemorrhage)**: 2 Discovery/pre-clinical
- **Maternal sepsis**: 2 Discovery/pre-clinical
- **Contraceptive methods**: 2 Discovery/pre-clinical
- **HTLV-1**: 2 Discovery/pre-clinical
- **HSV-2**: 2 Discovery/pre-clinical
- **Hypertensive disorders of pregnancy**: 2 Discovery/pre-clinical
- **Maternal abortion and miscarriage**: 2 Discovery/pre-clinical
- **Obstructed labour**: 2 Discovery/pre-clinical
- **Syphilis**: 2 Discovery/pre-clinical

*‘Other’ is defined as projects which follow a different development cycle than R&D projects which target the treatment of a disease, such as a technical lifecycle for devices.*
Companies are addressing seven diseases with priority gaps

What's missing?
HSV-2, Contraceptives, pre-eclampsia, syphilis

* There is one diagnostic project in the pipeline targeting both chlamydia and gonorrhoea.
Registration is lacking in low-income countries
Registration in LMICs is lacking, but positive exceptions for some medicines on the EML

<table>
<thead>
<tr>
<th>Disease</th>
<th>Medicine Details</th>
<th>Filings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast Cancer</td>
<td>trastuzumab (Ontruzant®), MSD***</td>
<td></td>
</tr>
<tr>
<td></td>
<td>VENTANA HER2 Dual ISH, Roche</td>
<td>5/6</td>
</tr>
<tr>
<td>Cervical Cancer</td>
<td>CINtec PLUS Cytology, Roche</td>
<td>1/5/8</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>DTaP, hep B, polio, Hib conjugate vaccine (Vaxelis®), MSD***</td>
<td>0</td>
</tr>
<tr>
<td>HIV/AIDS</td>
<td>dolutegravir (Tivicay PD), GSK</td>
<td>6/9/11</td>
</tr>
<tr>
<td></td>
<td>micafungin (Mycamine®), Astellas</td>
<td>6/15/9</td>
</tr>
<tr>
<td>Contraceptives</td>
<td>IUD levonorgestrel-releasing, (Mirena®), Bayer</td>
<td>10/32/22</td>
</tr>
</tbody>
</table>
Supranational agreements are focused on three SRHR health needs.
8 companies engage in supranational procurement
Company engagement in capacity building for SRHR varies across fields.
What can be done to improve access to SRHR products?

- Tailoring access strategies for more products, in all income groups
- Investing in R&D for product gaps relevant to women and girls in LMICs
- Engaging in supranational procurement and addressing gaps for NCDs
- Increasing the breadth of registration filings, especially across LICs
- Working in partnerships to build capacity and strengthen health systems
Access to Medicine Index 2022 Ranking
How the 20 companies compare?
2022 ACCESS TO MEDICINE INDEX – OVERALL RANKING

1 = 1 GSK plc

2 ▲ 3 Johnson & Johnson

3 ▲ 7 AstraZeneca plc

4 ▼ 2 Novartis AG

5 ▲ 8 Merck KGaA (Merck)

6 ▼ 4 Pfizer Inc

7 ▼ 6 Takeda Pharmaceutical Co, Ltd

8 ▼ 5 Sanofi

9 ▲ 13 Bayer AG

10 ▼ 9 Roche Holding AG

11 ▼ 10 Novo Nordisk A/S

12 ▼ 11 Eisai Co, Ltd

13 ▼ 12 Boehringer Ingelheim

14 = 14 Gilead Sciences

15 ▲ 19 Bristol Myers Squibb

16 ▼ 14 Astellas Pharma Inc

17 ▼ 16 Daiichi Sankyo Co, Ltd

18 ▼ 15 Merck & Co, Inc (MSD)

19 ▼ 17 AbbVie Inc

20 ▼ 18 Eli Lilly & Co
Feedback for the 2024 Index
Feedback for the 2024 Index

➢ For **contraceptives**, are there any recommendations for proxy products to understand the demand/need in certain countries?

➢ Is **local manufacturing** through technology transfer a possible approach to improving local/regional availability of these products?

➢ In **supranational procurement agreements**, what terms of the agreements are seen as best practice?

➢ In **capacity-building initiatives** for SRHR, what factors do companies use to assess where their resources are best needed?

➢ On **registration**, what factors impact the decision to file to register a product in a particular country? Do you feel collaborative registration procedures or proxy country procedures are useful mechanisms for expanding access?
Thank you!

Anne-Charlotte Douard, Government engagement and policy officer

acdouard@accesstomedicinefoundation.org
www.accesstomedicinefoundation.org